Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 2 full-time employees. The company went IPO on 2017-06-27. The firm is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is designed to modify SBMA through multiple mechanisms, including degradation of the mutant androgen receptor (AR) protein and stimulation of the Nrf1 and Nrf2 pathways, which are involved in protecting cells from oxidative stress that can lead to cell death. Baergic’s pipeline consists of a single compound, BAER-101, a novel α2/3 subtype-selective GABA A positive allosteric modulator.
Follow-Up Questions
¿Quién es el CEO de Avenue Therapeutics Inc?
Dr. Alexandra Maclean es el Chief Executive Officer de Avenue Therapeutics Inc, se unió a la empresa desde 2022.
¿Qué tal es el rendimiento del precio de la acción ATXI?
El precio actual de ATXI es de $0.7301, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Avenue Therapeutics Inc?
Avenue Therapeutics Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Avenue Therapeutics Inc?
La capitalización bursátil actual de Avenue Therapeutics Inc es $2.3M
¿Es Avenue Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Avenue Therapeutics Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta
